Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for ClinicalPractice
Current Pharmaceutical Design2022Vol. 28(27), pp. 2241–2259
Citations Over TimeTop 10% of 2022 papers
Giovanni Martinotti, Stefania Chiappini, Alessio Mosca, Andrea Miuli, Maria Chiara Santovito, Mauro Pettorruso, Valentin Yurievich Skryabin, Stefano L. Sensi, Massimo Di Giannantonio
Abstract
The findings highlight the use of SGA for the treatment of psychotic symptoms in comorbidity with substance use. Future studies on people with dual diagnosis and focused on long-term evaluations are warranted and need to investigate the efficacy of newly introduced molecules, such as partial D2 agonists and longacting injectable antipsychotics.
Related Papers
- → Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats(2008)29 cited
- → Aripiprazole versus ziprasidone for schizophrenia(2017)1 cited
- → EFFECTIVENESS OF SWITCHING FROM ARIPIPRAZOLE TO ZIPRASIDONE IN PATIENTS WITH SCHIZOPHRENIA(2010)
- The Clinical Research of Aripiprazole Combined with Ziprasidone in the Treatment of Elderly Schizophrenia(2014)
- Effects of Ziprasidone and Aripiprazole on serum prolactin and body weight(2013)